Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy

[1] Mountain CF(1997)Revisions in the international system for staging lung cancer Chest 111 1710-1717

[2] Winton TL(2005)et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10 N Engl J Med 352 2289-2297

[3] Livingston R(2006)DNA Repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med. 355 983-991

[4] Johnson D(2001)Breast cancer survival and in vitro tumor response in the extreme drug resistance assay Breast Cancer Res Treatment. 66 225-237

[5] Olaussen KA(2002)Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients Gynecol Oncol. 87 8-16

[6] Dunant A(2004)A prospective blinded study of predictive value of extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma J Neuro-Oncol. 66 365-375

[7] Fouret P(2006)Prevalence of in vitro extreme chemotherapy resistance in resected non-small cell lung cancer Ann Thor Surg. 81 440-447

[8] Brambilla E(2007)Chemotherapy resistance and oncogene expression in non-small cell lung cancer J Thorac Cardiovasc Surg. 133 352-363

[9] Mehta R(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med. 346 92-98

[10] Bomstein R(1990)Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharacologic drug exposures J Natl Cancer Inst. 82 582-588

[1] Mountain CF(1997)Revisions in the international system for staging lung cancer Chest 111 1710-1717

[2] Winton TL(2005)et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10 N Engl J Med 352 2289-2297

[3] Livingston R(2006)DNA Repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med. 355 983-991

[4] Johnson D(2001)Breast cancer survival and in vitro tumor response in the extreme drug resistance assay Breast Cancer Res Treatment. 66 225-237

[5] Olaussen KA(2002)Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients Gynecol Oncol. 87 8-16

[6] Dunant A(2004)A prospective blinded study of predictive value of extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma J Neuro-Oncol. 66 365-375

[7] Fouret P(2006)Prevalence of in vitro extreme chemotherapy resistance in resected non-small cell lung cancer Ann Thor Surg. 81 440-447

[8] Brambilla E(2007)Chemotherapy resistance and oncogene expression in non-small cell lung cancer J Thorac Cardiovasc Surg. 133 352-363

[9] Mehta R(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med. 346 92-98

[10] Bomstein R(1990)Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharacologic drug exposures J Natl Cancer Inst. 82 582-588